Potential 100 bagger Biotech missed by the market, page-1434

Great analysis! For the AD research arm, what you are suggesting sounds possible, see here and below snip



I think it may be for the other research arms too, especially when you think about the companies research partners they have been announcing recently and the data they are going to be able to get from the Phase 1 trials with the help of these research partners that are leaders in their field - in theory what you are suggesting could be possible, I think this would be something to pose to the MD Matt!

In my response yesterday, whilst I said they should be looking for fast track, a better answer would be that they should review these options with the FDA or an advisor (e.g. Camargo that assists with IND meetings) and select the best outcome for the company/drug. Also see snip below:


I hope the company clarifies their plans for FDA approval with shareholders in the near future